Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 341-349

  Moriconi, F ^a   Colombatto, P ^a   Coco, B ^a   Ciccorossi, P ^a   Oliveri, F ^a   Flichman, D ^a   Maina, A M ^a   Sacco, R ^a   Bonino, F ^b   Brunetto, M R ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antivirals; HBV; Resistance; Viral load

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS ENZYME;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG RESPONSE; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; UNIVARIATE ANALYSIS; VIREMIA; VIRUS LOAD;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; NUCLEOTIDES; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; VIREMIA;

EID: 34547849667     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm187     Document Type: Article

References (36)

1. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: Natural history and treatment. Semin Liver Dis 2006; 26: 116-29.
2. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
3. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45 507-39.
4. Fung SK, Lok AS. Management of hepatitis B patients with anti-viral resistance. Antivir Ther 2004; 9: 1013-26.
5. Locamini S, Hatzakis A, Heathcote J et al. Management of anti-viral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-93.
6. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 2006; 71: 206-15.
7. Villamil FG. Hepatitis B: Progress in the last 15 years. Liver Transpl 2002; 8: 59-66.
8. Bartholomeusz A, Locamini S. Antiviral drug resistance: Clinical consequences and molecular aspects. Semin Liver Dis 2006; 26 162-70.
9. Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
10. Perrillo R. Current treatment of chronic hepatitis B: Benefits and limitations. Semin Liver Dis 2005; 25: 20-8.
11. Villet S, Pichoud C, Villeneuve JP et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
12. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-91.
13. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patents with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
14. Lampertico P, Viganò M, Manetti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
15. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
16. Gerolami R, Bourliere M, Colson P et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: Report of two cases. Antivir Ther 2006; 11: 1103-6.
17. Colloredo G, Bellati G, Leandro G et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. J Hepatol 1996; 25 644-8.
18. Chong Y, Stuyver L, Otto MJ et al. Mechanism of antiviral activities of 3′-substituted L-nucleosides against 3TC-resistant HBV polymerase: A molecular modelling approach. Antivir Chem Chemother 2003; 14: 309-19.
19. Rapti I, Dimou E, Mitsoula P et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitits B. Hepatology 2007; 45: 307-13.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B a antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
21. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
22. Locamini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44: 422-31.
23. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
24. Fung SK, Bok Chae H, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatology 2006; 44: 283-90.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
26. Tenney DJ, Langley DR, Oliver AJ et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004; 40: 245 (abstract).
27. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
28. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
29. Yeh CT, Chien RN, Chu CM et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-26.
30. Brunelle MN, Jaquard AC, Pichoud C et al. Susceptibility to antivirals of human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
31. Locamini S, Shaw T, Sozzi T et al. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro. Hapatology 2004; 40: 244 (abstract).
32. Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006; 78: 1025-34.
33. Yim HJ, Hussain M, Lyu Y et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
34. - conformation. Biophys J 2000; 79: 2754-60.
35. Bartholomeusz A, Tehan BG, Chalmers DK et al. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-60.
36. Lee YS, Chung YH, Ryu SH et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy. Hepatology 2005; 42: 575A (abstract 965).